Structure via PubChem · Public domain (PubChem)
rasagiline
Sign in to saveAlso known as Azilect®, TVP-1012, (R)-indan-1-yl-prop-2-ynyl-amine, (1R)-N-propargylindan-1-amine, (R)-N-2-Propynyl-1-indanamine, RAS, (1R)-N-Propargylindan-1-amine, (R)-Indan-1-yl-prop-2-ynyl-amine
Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The drug is taken by mouth.
Key facts
- Drug.Verifiedfields
- verified
- Drug.verifiedrevid
- 464380249
- Drug.image
- Rasagiline2DCSD.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150
- Drug.image2
- Rasagiline 3D Ball-and-Stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Azilect, others
- Drug.MedlinePlus
- a606017
- Drug.DailyMedID
- Rasagiline
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.class
- Monoamine oxidase inhibitor; Antiparkinsonian
- Drug.ATC_prefix
- N04
- Drug.ATC_suffix
- BD02
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C12H13N
- Molecular weight
- 171.24 g/mol
- IUPAC name
- (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
- SMILES
- C#CCN[C@@H]1CCC2=CC=CC=C12
- InChIKey
- RUOKEQAAGRXIBM-GFCCVEGCSA-N
- XLogP
- 1.8
- Polar surface area
- 12 Ų
- H-bond donors
- 1
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Research
873 papers- Rasagiline.Drugs & aging · 2005
- Rasagiline for the treatment of Parkinson's disease: an update.Expert opinion on pharmacotherapy · 2015
- Rasagiline in neurodegeneration.Experimental neurology · 2008
- Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2020
- Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials.Journal of psychopharmacology (Oxford, England) · 2022
via PubMed
~28 min read
Encyclopedic overview
27 sectionsContents
- Medical uses
- Parkinson's disease
- Available forms
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Pharmacodynamics
- Monoamine oxidase inhibitor
- Other actions
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- History
- Society and culture
- Names
- Generic forms
- Research
- Neurodegenerative diseases
- Psychiatric disorders
- Other conditions
- Notes
- References
Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The drug is taken by mouth.
Side effects of rasagiline include insomnia and orthostatic hypotension, among others. Rasagiline acts as an inhibitor of the enzyme monoamine oxidase (MAO) and hence is a monoamine oxidase inhibitor (MAOI). More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B). The drug is thought to work by increasing levels of the monoamine neurotransmitter dopamine in the brain. Rasagiline shows pharmacological differences from the related drug selegiline, including having no amphetamine-like metabolites, monoamine-releasing activity, or monoaminergic activity enhancer actions, which may result in clinical differences between the medications.
Excerpted from Wikipedia’s “rasagiline” article, available under the CC BY-SA 4.0 licence.